# Aptevo Therapeutics Inc.: financial statements, quarterly APVO · Nasdaq · CIK 1671584 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/apvo.md) · [Financials](/companies/apvo/financials.md) · [Filings](/companies/apvo/filings.md) · [Insiders](/companies/apvo/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/apvo/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Cost of revenue | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Research and development | $k | [3,887](/filings/0000950170-24-122837.md) | [3,591 d](/filings/0000950170-25-020467.md) | [3,752](/filings/0000950170-25-072622.md) | [3,643](/filings/0000950170-25-106247.md) | [3,103](/filings/0001193125-25-269598.md) | [3,880 d](/filings/0001193125-26-126278.md) | [3,633](/filings/0001193125-26-221661.md) | [3,328](/filings/0001193125-26-350559.md) | [4,044](/filings/0001193125-25-269598.md) | [3,535 d](/filings/0001193125-26-126278.md) | [3,924](/filings/0001193125-26-221661.md) | [3,696](/filings/0001193125-26-350559.md) | | Selling, general and administrative | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating income | $k | [(6,561)](/filings/0000950170-24-122837.md) | [(6,384) d](/filings/0000950170-25-020467.md) | [(6,983)](/filings/0000950170-25-072622.md) | [(6,024)](/filings/0000950170-25-106247.md) | [(5,213)](/filings/0001193125-25-269598.md) | [(6,382) d](/filings/0001193125-26-126278.md) | [(6,480)](/filings/0001193125-26-221661.md) | [(6,226)](/filings/0001193125-26-350559.md) | [(7,610)](/filings/0001193125-25-269598.md) | [(5,996) d](/filings/0001193125-26-126278.md) | [(6,837)](/filings/0001193125-26-221661.md) | [(6,443)](/filings/0001193125-26-350559.md) | | Income tax | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net income | $k | [(6,334)](/filings/0000950170-24-122837.md) | [(5,903) d](/filings/0000950170-25-020467.md) | [(6,834)](/filings/0001193125-25-269598.md) | [(5,883)](/filings/0001193125-25-269598.md) | [(5,101)](/filings/0001193125-25-269598.md) | [(6,312) d](/filings/0001193125-26-126278.md) | [(6,408)](/filings/0001193125-26-350559.md) | [(6,204)](/filings/0001193125-26-350559.md) | [(7,549)](/filings/0001193125-25-269598.md) | [(5,806) d](/filings/0001193125-26-126278.md) | [(6,697)](/filings/0001193125-26-350559.md) | [(6,356)](/filings/0001193125-26-350559.md) | | Diluted EPS | $ per share | [(22.16)](/filings/0000950170-24-122837.md) | not reported | [(368.21)](/filings/0000950170-25-072622.md) | [(1236.96)](/filings/0000950170-25-106247.md) | [(357.86)](/filings/0001193125-25-269598.md) | not reported | [(1581.81)](/filings/0001193125-26-221661.md) | [(151.29)](/filings/0001193125-26-350559.md) | [(2.23)](/filings/0001193125-25-269598.md) | not reported | [(6.41)](/filings/0001193125-26-221661.md) | [(5.31)](/filings/0001193125-26-350559.md) | | Basic EPS | $ per share | [(22.16)](/filings/0000950170-24-122837.md) | not reported | [(368.21)](/filings/0000950170-25-072622.md) | [(1236.96)](/filings/0000950170-25-106247.md) | [(357.86)](/filings/0001193125-25-269598.md) | not reported | [(1581.81)](/filings/0001193125-26-221661.md) | [(151.29)](/filings/0001193125-26-350559.md) | [(2.23)](/filings/0001193125-25-269598.md) | not reported | [(6.41)](/filings/0001193125-26-221661.md) | [(5.31)](/filings/0001193125-26-350559.md) | - Revenue: not reported - Cost of revenue: not reported - Research and development: us-gaap:ResearchAndDevelopmentExpense - Selling, general and administrative: not reported - Operating income: us-gaap:OperatingIncomeLoss - Income tax: not reported - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $m | [19.1](/filings/0000950170-23-063379.md) | [16.9](/filings/0000950170-25-020467.md) | [10.3](/filings/0000950170-25-072622.md) | [8.1](/filings/0000950170-25-106247.md) | [7.8](/filings/0001193125-25-269598.md) | [8.7](/filings/0001193125-26-126278.md) | [2.1](/filings/0001193125-26-221661.md) | [9.4](/filings/0001193125-26-350559.md) | [21.1](/filings/0001193125-25-269598.md) | [21.6](/filings/0001193125-26-350559.md) | [14.5](/filings/0001193125-26-221661.md) | [9.8](/filings/0001193125-26-350559.md) | | Current assets | $m | [21.1](/filings/0000950170-23-063379.md) | [19.1](/filings/0000950170-25-020467.md) | [12.1](/filings/0000950170-24-055096.md) | [9.6](/filings/0000950170-24-093366.md) | [10.0](/filings/0000950170-24-122837.md) | [10.7](/filings/0001193125-26-126278.md) | [3.6](/filings/0000950170-25-072622.md) | [11.1](/filings/0000950170-25-106247.md) | [22.6](/filings/0001193125-25-269598.md) | [23.1](/filings/0001193125-26-350559.md) | [16.0](/filings/0001193125-26-221661.md) | [10.8](/filings/0001193125-26-350559.md) | | Total assets | $m | [27.1](/filings/0000950170-23-063379.md) | [24.8](/filings/0000950170-25-020467.md) | [17.6](/filings/0000950170-24-055096.md) | [14.9](/filings/0000950170-24-093366.md) | [15.1](/filings/0000950170-24-122837.md) | [15.6](/filings/0001193125-26-126278.md) | [8.3](/filings/0000950170-25-072622.md) | [15.6](/filings/0000950170-25-106247.md) | [27.0](/filings/0001193125-25-269598.md) | [27.2](/filings/0001193125-26-350559.md) | [19.9](/filings/0001193125-26-221661.md) | [14.5](/filings/0001193125-26-350559.md) | | Current liabilities | $m | [6.8](/filings/0000950170-23-063379.md) | [7.2](/filings/0000950170-25-020467.md) | [6.3](/filings/0000950170-24-055096.md) | [5.4](/filings/0000950170-24-093366.md) | [5.9](/filings/0000950170-24-122837.md) | [6.2](/filings/0001193125-26-126278.md) | [5.4](/filings/0000950170-25-072622.md) | [4.9](/filings/0000950170-25-106247.md) | [5.6](/filings/0001193125-25-269598.md) | [6.1](/filings/0001193125-26-350559.md) | [4.8](/filings/0001193125-26-221661.md) | [5.2](/filings/0001193125-26-350559.md) | | Total liabilities | $m | [12.4](/filings/0000950170-23-063379.md) | [12.6](/filings/0000950170-25-020467.md) | [11.5](/filings/0000950170-24-055096.md) | [10.5](/filings/0000950170-24-093366.md) | [10.7](/filings/0000950170-24-122837.md) | [10.8](/filings/0001193125-26-126278.md) | [9.8](/filings/0000950170-25-072622.md) | [9.1](/filings/0000950170-25-106247.md) | [9.6](/filings/0001193125-25-269598.md) | [9.8](/filings/0001193125-26-350559.md) | [8.3](/filings/0001193125-26-221661.md) | [8.5](/filings/0001193125-26-350559.md) | | Long-term debt | $m | [0.0](/filings/0000950170-23-063379.md) | [0.0](/filings/0000950170-24-025428.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Shareholders' equity | $m | [14.7](/filings/0000950170-24-122837.md) | [12.2](/filings/0001193125-26-126278.md) | [6.1](/filings/0001193125-25-269598.md) | [4.5](/filings/0001193125-25-269598.md) | [4.4](/filings/0001193125-25-269598.md) | [4.8](/filings/0001193125-26-350559.md) | [(1.5)](/filings/0001193125-26-350559.md) | [6.5](/filings/0001193125-26-350559.md) | [17.4](/filings/0001193125-25-269598.md) | [17.4](/filings/0001193125-26-350559.md) | [11.6](/filings/0001193125-26-350559.md) | [6.0](/filings/0001193125-26-350559.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Long-term debt: us-gaap:LongTermDebt - Current portion of debt: not reported - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $k | [(6,240) d](/filings/0000950170-24-122837.md) | [(5,253) d](/filings/0000950170-25-020467.md) | [(6,651)](/filings/0000950170-25-072622.md) | [(6,153) d](/filings/0000950170-25-106247.md) | [(5,222) d](/filings/0001193125-25-269598.md) | [(5,759) d](/filings/0001193125-26-126278.md) | [(6,575)](/filings/0001193125-26-221661.md) | [(7,093) d](/filings/0001193125-26-350559.md) | [(6,688) d](/filings/0001193125-25-269598.md) | [(5,236) d](/filings/0001193125-26-126278.md) | [(7,965)](/filings/0001193125-26-221661.md) | [(5,454) d](/filings/0001193125-26-350559.md) | | Capital expenditure | $k | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: not reported ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | thousands of shares | [5,091](/filings/0000950170-23-063379.md) | [160](/filings/0000950170-24-055096.md) | [147](/filings/0000950170-24-093366.md) | [286](/filings/0000950170-24-122837.md) | [18.6](/filings/0000950170-25-072622.md) | [4.8](/filings/0000950170-25-106247.md) | [14.3](/filings/0001193125-25-269598.md) | [4.1](/filings/0001193125-26-221661.md) | [41.0](/filings/0001193125-26-350559.md) | [4,049](/filings/0001193125-25-269598.md) | [1,061](/filings/0001193125-26-221661.md) | [1,196](/filings/0001193125-26-350559.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Shares outstanding: 1,801,970 at 2026-08-14, from the cover of the [10-Q filed 2026-08-14](/filings/0001193125-26-350559.md) (dei:EntityCommonStockSharesOutstanding). Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.